World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
97
Citations
44172
World Ranking
9139
National Ranking
4714

Alona Muzikansky publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Alona Muzikansky sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 366 publications — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Alona Muzikansky D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Alona Muzikansky sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 97 D-Index — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Alona Muzikansky is affiliated with Harvard University in the United States and has a research focus primarily within the field of Medicine, with a substantial number of publications addressing Oncology, Pulmonary and Respiratory Medicine, Neurology, Genetics, and Molecular Biology. Their work spans multiple topics related to cancer and neurological disorders.

The scientist's research interests prominently include:

  • Neurofibromatosis and Schwannoma Cases
  • Glioma Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Meningioma and schwannoma management
  • Brain Metastases and Treatment
  • Smoking Behavior and Cessation
  • Cancer Immunotherapy and Biomarkers

Muzikansky has contributed to several recent papers, notable for their relevance to neuro-oncology, cancer immunotherapy, and disease mechanism study. Among these publications are:

  • "Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer's disease" (2020), published in Nature Communications
  • "Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma" (2020), published in Clinical Cancer Research
  • "Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer" (2020), published in JAMA
  • "Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results" (2021), published in Neuro-Oncology
  • "A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor" (2021), published in Journal of Thoracic Oncology

The frequent publication venues for Muzikansky's work include:

  • Neuro-Oncology
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Neurology
  • bioRxiv (Cold Spring Harbor Laboratory)

There is a pattern of collaboration with several co-authors who have contributed extensively to similar research areas. These frequent collaborators include:

  • Scott R. Plotkin
  • Justin T. Jordan
  • Patrick Y. Wen
  • David A. Reardon
  • Elyse R. Park

Alona Muzikansky's work addresses critical issues in cancer treatment, neurological disorders, and behavioral health interventions related to smoking cessation, reflecting integration of molecular, clinical, and therapeutic research approaches. Their publication record indicates consistent contribution to oncology and neurology literature with interdisciplinary collaboration.

Best Publications

  • Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer

    Jennifer S. Temel;Joseph A. Greer;Alona Muzikansky;Emily R. Gallagher

  • Isolation of rare circulating tumour cells in cancer patients by microchip technology.

    Sunitha Nagrath;Lecia V. Sequist;Shyamala Maheswaran;Daphne W. Bell;Daphne W. Bell

  • Detection of Mutations in EGFR in Circulating Lung-Cancer Cells

    Shyamala Maheswaran;Lecia V. Sequist;Sunitha Nagrath;Lindsey Ulkus

  • First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

    Lecia V. Sequist;Renato G. Martins;David Spigel;Steven M. Grunberg

  • Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

    A. D. Norden;G. S. Young;K. Setayesh;A. Muzikansky

  • Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial

    Jennifer S. Temel;Joseph A. Greer;Areej El-Jawahri;William F. Pirl

  • Effect of Early Palliative Care on Chemotherapy Use and End-of-Life Care in Patients With Metastatic Non–Small-Cell Lung Cancer

    Joseph A. Greer;William F. Pirl;Vicki A. Jackson;Alona Muzikansky

  • Tumor Lymphangiogenesis : A Novel Prognostic Indicator for Cutaneous Melanoma Metastasis and Survival

    Soheil S. Dadras;Thomas Paul;Jennifer Bertoncini;Lawrence F. Brown

  • Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors

    Matthew H. Kulke;Keith Stuart;Peter C. Enzinger;David P. Ryan

  • Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic Adenocarcinoma

    Cristina R. Ferrone;Dianne M. Finkelstein;Sarah P. Thayer;Alona Muzikansky

  • Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

    Andrew X. Zhu;Lawrence S. Blaszkowsky;David P. Ryan;Jeffrey W. Clark

  • Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

    Zofia Piotrowska;Matthew J. Niederst;Chris A. Karlovich;Heather A. Wakelee

  • The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas

    Arnab Chakravarti;Gary Zhai;Yoshiyuki Suzuki;Sormeh Sarkesh

  • Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes

    Soheil S Dadras;Bernhard Lange-Asschenfeldt;Paula Velasco;Lynh Nguyen

  • The Effect of Surgery and Grade on Outcome of Gastrointestinal Stromal Tumors

    Jean Pierre E N Pierie;Umar H Choudry;Alona Muzikansky;Beow Yong Yeap

  • Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

    L. V. Sequist;R. S. Heist;A. T. Shaw;P. Fidias

  • Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

    Andrew X Zhu;Jeffrey A Meyerhardt;Lawrence S Blaszkowsky;Avinash R Kambadakone

  • EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

    Nicolas Marcoux;Scott N. Gettinger;Grainne O’Kane;Kathryn C. Arbour

  • Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

    Tilak K. Sundaresan;Lecia V. Sequist;John Victor Heymach;Gregory J. Riely

  • Mucin-Producing Neoplasms of the Pancreas: An Analysis of Distinguishing Clinical and Epidemiologic Characteristics

    Stefano Crippa;Carlos Fernández–del Castillo;Roberto Salvia;Dianne Madelyn Finkelstein

Frequent Co-Authors

Patrick Y. Wen
Patrick Y. Wen Harvard University
Lecia V. Sequist
Lecia V. Sequist Harvard University
David A. Reardon
David A. Reardon Harvard University
Jennifer S. Temel
Jennifer S. Temel Harvard University
Tracy T. Batchelor
Tracy T. Batchelor Brigham and Women's Hospital
Rameen Beroukhim
Rameen Beroukhim Harvard University
Rakesh K. Jain
Rakesh K. Jain Harvard University
Keith L. Ligon
Keith L. Ligon Harvard University
Alice T. Shaw
Alice T. Shaw Harvard University
Dan G. Duda
Dan G. Duda Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The field of medicine in the USA extends far beyond the traditional MD pathway. Today, a variety of online degrees open doors to rewarding careers in healthcare, offering flexibility for busy students or working professionals.

For those interested in mental health, advanced practice nursing is a rapidly growing area. If you already hold a master's in nursing, you could consider the fastest post master's pmhnp programs, which allow you to qualify as a Psychiatric Mental Health Nurse Practitioner in less time.

Administration is another popular avenue. If cost is a concern, exploring the cheapest online healthcare administration degree options can help you find accredited programs that fit your budget. For those seeking advanced qualifications, understanding the cost of mha degree programs is essential in planning your education expenses.

Aspiring doctoral-level nurses can find high-quality yet cheap online dnp programs to further their clinical expertise. These diverse online pathways make it easier than ever to build a healthcare career tailored to your goals and financial needs.

Best Scientists Citing Alona Muzikansky

Trending Scientists

Recently Published Articles